RU2007116969A - Средство для профилактики или лечения метаболического синдрома - Google Patents

Средство для профилактики или лечения метаболического синдрома Download PDF

Info

Publication number
RU2007116969A
RU2007116969A RU2007116969/15A RU2007116969A RU2007116969A RU 2007116969 A RU2007116969 A RU 2007116969A RU 2007116969/15 A RU2007116969/15 A RU 2007116969/15A RU 2007116969 A RU2007116969 A RU 2007116969A RU 2007116969 A RU2007116969 A RU 2007116969A
Authority
RU
Russia
Prior art keywords
prevention
treatment
metabolic syndrome
salt
pparγ agonist
Prior art date
Application number
RU2007116969/15A
Other languages
English (en)
Inventor
Нобухиро НИСИГАКИ (JP)
Нобухиро НИСИГАКИ
Original Assignee
Такеда Фармасьютикал Компани Лимитед (Jp)
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2007116969(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед (Jp), Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед (Jp)
Publication of RU2007116969A publication Critical patent/RU2007116969A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (4)

1. Средство для профилактики или лечения метаболического синдрома, которое содержит комбинацию 2-этокси-1-[[2'-(5-оксо-2,5-дигидро-1,2,4-оксадиазол-3-ил) бифенил-4-ил]метил]-1H-бензимидазол-7-карбоновой кислоты или ее соли, или ее пролекарства и вещества, подобного агонисту PPARγ.
2. Средство согласно п.1, в котором вещество, подобное агонисту PPARγ, представляет собой пиоглитазон или его соль.
3. Способ профилактики или лечения метаболического синдрома у млекопитающего, который содержит введение млекопитающему 2-этокси-1-[[2'-(5-оксо-2,5-дигидро-1,2,4-оксадиазол-3-ил)бифенил-4-ил]метил]-1H-бензимидазол-7-карбоновой кислоты или ее соли, или ее пролекарства и вещества, подобного агонисту PPARγ.
4. Применение 2-этокси-1-[[2'-(5-оксо-2,5-дигидро-1,2,4-оксадиазол-3-ил)бифенил-4-ил]метил]-1H-бензимидазол-7-карбоновой кислоты или ее соли, или ее пролекарства в комбинации с веществом, подобным агонисту PPARγ, для изготовления средства для профилактики или лечения метаболического синдрома.
RU2007116969/15A 2004-10-07 2005-10-06 Средство для профилактики или лечения метаболического синдрома RU2007116969A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004294889 2004-10-07
JP2004-294889 2004-10-07
JP2005-125373 2005-04-22
JP2005125373 2005-04-22

Publications (1)

Publication Number Publication Date
RU2007116969A true RU2007116969A (ru) 2008-11-20

Family

ID=35517142

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007116969/15A RU2007116969A (ru) 2004-10-07 2005-10-06 Средство для профилактики или лечения метаболического синдрома

Country Status (17)

Country Link
US (1) US20070270477A1 (ru)
EP (1) EP1799203A1 (ru)
JP (1) JP2008515767A (ru)
KR (1) KR20070073872A (ru)
AR (1) AR052015A1 (ru)
AU (1) AU2005290394A1 (ru)
BR (1) BRPI0516246A (ru)
CA (1) CA2583768A1 (ru)
CR (1) CR9074A (ru)
IL (1) IL182055A0 (ru)
MX (1) MX2007003716A (ru)
NO (1) NO20071889L (ru)
PE (1) PE20060971A1 (ru)
RU (1) RU2007116969A (ru)
TW (1) TW200616625A (ru)
UY (1) UY29155A1 (ru)
WO (1) WO2006038722A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126135A1 (en) * 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl
JP2008195625A (ja) * 2007-02-08 2008-08-28 Pharma Frontier Kk Ｇ蛋白質共役型レセプター抑制剤および医薬
CA2782224A1 (en) * 2009-11-30 2011-06-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Azilsartan organic amine salts, preparation method and use thereof
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2666773B1 (en) 2011-01-20 2017-07-26 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
PT914158E (pt) * 1996-04-05 2002-11-29 Takeda Chemical Industries Ltd Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina
PL342684A1 (en) * 1998-03-04 2001-07-02 Takeda Chemical Industries Ltd Preperation featured by reterded release of aii antagonist, production and application of such preparation
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003256419A1 (en) * 2002-08-21 2004-03-11 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
US7582662B2 (en) * 2002-12-27 2009-09-01 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Also Published As

Publication number Publication date
US20070270477A1 (en) 2007-11-22
MX2007003716A (es) 2007-04-23
CR9074A (es) 2007-08-28
BRPI0516246A (pt) 2008-08-26
UY29155A1 (es) 2006-02-24
KR20070073872A (ko) 2007-07-10
WO2006038722A1 (en) 2006-04-13
CA2583768A1 (en) 2006-04-13
JP2008515767A (ja) 2008-05-15
AR052015A1 (es) 2007-02-28
TW200616625A (en) 2006-06-01
AU2005290394A1 (en) 2006-04-13
IL182055A0 (en) 2007-07-24
PE20060971A1 (es) 2006-11-15
NO20071889L (no) 2007-06-26
EP1799203A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
RU2007139928A (ru) Производное бензимидазола и применение в качестве антагониста ангиотензина
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
DK1973540T3 (da) Anvendelse af benzokondenserede heterocycliske sulfamidderivater til behandling af smerte
CL2007001870A1 (es) Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
JP2013531028A5 (ru)
RU2007116969A (ru) Средство для профилактики или лечения метаболического синдрома
JP2005263780A5 (ru)
CR10010A (es) Derivados de pirimidina, derivados de benzodiazepinilo y composiciones farmaceuticas que contienen los mismos
AR052052A1 (es) Terapia de combinacion
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
WO2008027963A3 (en) Nsaid dose unit formulations with h2-receptor antagonists and methods of use
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
CL2007002195A1 (es) Compuesto n-((1r,2s,5r)-5-(isopropil(metil)amino)-2-((s)-2-oxo-3-(6-(trifluorometil)quinazolin-4-ilamino)pirrolidin-1-il)ciclohexil)acetamida; forma cristalina del compuesto; composicion farmaceutica; y uso en el tratamiento de enfermedades tales com
CL2007003348A1 (es) Procedimiento de preparacion de 4,4'-(1-metil-1,2-etandiil)-bis-(2,6-piperazindiona); compuesto intermediario; procedimiento de preparacion y uso.
BRPI0806529A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
CL2011000187A1 (es) Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii.
PE20050335A1 (es) Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
RU2009127776A (ru) Профилактическое или терапевтическое средство от алопеции
UA92485C2 (ru) Производная бензамида и ее применение как антагониста ангиотензина ии
TH82345B (th) สารสำหรับการป้องกัน หรือรักษากลุ่มอาการเมแทบอลิค
WO2009024820A3 (en) Therapeutic treatment 014
BRPI0416588A (pt) uso farmacêutico adicional

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20081110